Cancer research 2001: Drug resistance, new targets and drug combinations

Drug Resistance Updates

Volumn 4, Issue 3, 2001, Pages 197-209

  Broxterman, Henk J ^a,b   Georgopapadakou, Nafsika ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NewBiotics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 AMINO 4 (3 PYRIDYL) 4H NAPHTHO[1,2 B]PYRAN 3 CARBONITRILE; 2 METHOXYESTRADIOL; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 6 CYCLOHEXYLMETHOXY 2 (4 SULFAMOYLANILINO)PURINE; AF 13925; AFELETECAN; AG 13764; AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; AMP 404; ANGINEX; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BMS 250749; BMS 251873; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CARBAZOLE DERIVATIVE; CGP 85715; CLOPIDOGREL; D 24851; D 64131; DE 310; DIFLOMOTECAN; DNA TOPOISOMERASE INHIBITOR; E 173; EDOTECARIN; ENDOSTATIN; ER 6820300; EXATECAN; F 11782; FB 642; GEFITINIB; GFB 111; GFB 116; GIMATECAN; GW 2286; IDN 5390; IMATINIB; IRINOTECAN; L 778123; LB 42906; LONAFARNIB; LURTOTECAN; LY 290293; MOBILETREX; NUCLEOSIDE ANALOG; ORTATAXEL; PACLITAXEL POLIGLUMEX; PEMETREXED; PYRAN DERIVATIVE; RALTITREXED; RUBITECAN; S 137; S 247; SCH 221153; SORAFENIB; ST 1646; TILMACOXIB; TIPIFARNIB; TOPOTECAN; TRABECTEDIN; TXD 258; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; WAR 196; WF 536; WX 293; WX 360; WX UK 1; X 469;

ANGIOGENESIS; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CELL CYCLE; CELL TRANSPORT; CLINICAL TRIAL; DRUG TARGETING; GENE EXPRESSION; HUMAN; MEDICAL SOCIETY; META ANALYSIS; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TECHNOLOGY;

EID: 0035177001     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2001.0216     Document Type: Editorial

References (82)

1. 89th Annual Meeting of the American Association for Cancer Research (AACR)
2. Cancer research 2000: Drug resistance, new targets and drugs in development
3. Apoptosis is critical for drug response in vivo
4. Does resistance to apoptosis affect clinical response to antitumor drugs?
5. Disrupting the p53-mdm2 interaction as a potential therapeutic modality
6. Turning P53 on or off: Either way may treat cancer
7. Potential role for stathmin in modulation of chemosensitivity
8. DNA damage increases sensitivity to Vinca alkaloids and decreases sensitivity to taxanes through P53-dependent repression of microtubule-associated protein 4
9. A phase I/II clinical trial of doxorubicin and vinorelbine: Effects on p53 and microtubule-associated protein 4 (MAP 4) expression in patients with advanced breast cancer
10. Topoisomerase inhibitors: Selectivity and cellular resistance
11. Cellular pharmacokinetic andpharmacodynamic aspects of response to camptothecins: Perspectives to improve response
12. Modulation of camptothecin free drug levels in human blood
13. Murine breast cancer resistance protein BCRPI mediates two distinct MDR phenotypes
14. Mutation conferring altered substrate specificity in the ABC half-transporter MXR/BCRP/ABCPI/ABCG2
15. Primary versus secondary activation of CPT-II: A role for tumor glucuronidases?
16. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: Contribution of drug transport proteins
17. Breast cancer resistance protein (BCRP) preferentially transports SN-38, the active metabolite of irinotecan, rather than SN-38-glucuronide conjugate
18. Liposomal formulations of anticancer drugs: Selectivity and effectiveness
19. Thymidylate synthase quantitation predicts for disease-free survival in colorectal cancer patients receiving adjuvant 5-fluorouracil
20. Camptothecin co-polymer conjugates: A novel perspective in lopoisomerase I-based anti-tumor therapy
21. Combination chemotherapy of a novel pyrazoloacridone derivative, KW-2170, and SN-38: Synergy and mechanisms
22. Small cell and its stroma: Determinant of pan-resistance?
23. The tumor environment as a determinant of drug response and resistance
24. Investigation of the effects of cellular attachment and integrin signalling on tumor cell viability and sensitivity to antitumor drugs in vitro
25. Fibronectin adhesion via B: Integrins confers resistance to topoisomerase (Topo) II inhibitors by decreasing initial DNA damage secondary to to altered TOPO lib activity and nuclear binding
26. Atra and 13-Cisra induce b1 integrin and paxillin in association with cell adhesion triggering resistance to topotecan in HeLa S cervical cancer cells
27. Role of bystander effect in cell killing by genotoxic stress: Lessons from kinesin-mediated drug sensitivity
28. Cloning mammalian genes by expression selection of genetic suppressor elements: Association of kinesin with drug resistance and cell immortalization
29. cDNA technologies and their application to drug resistance: Power, potential and problems
30. Gene expression patterns of the cisplatin-induced cellular injury response
31. Identification of genes with carboplatin chemoresistance by staqndardized RT (staRT)-PCR analysis of a sensitive (H460) and a resistance (H1435) human non-small cell lung cancer cell line
32. Gene expression profiles associated with platinum drug sensitivity and resistance in human ovarian cancer cells
33. A comparison of gene expression analyses in SKOV-3 wild-type and resistant ovarian carcinomacells following treatment with cisplatin and a non-cross-resistaqnt platinum analogue, ZD-0473
34. Investigation of gene expression profiles of oxaliplatin-resistant cell lines using microarray data
35. The genetic basis of response to chemotherapy in ovarian cancer
36. A DNA microarray-based approach to identify genes associated with chemoresistance under tumor microenvironment
37. Application if differential gene expression to examine the form of resistance called the contact effect
38. Analysis of global gene expression patterns in chemoresistant cencer cell lines using cDNA array
39. cDNA microarray analysius of paclitaqxel-treated ovarian carcinoma xenografts
40. Doxorubicin-induced alterations of te gene expression profiles of leukaemia cells in culture using cDNA microarrays
41. Prolonged hypoxic conditioning of the human colon carcinoma cell line HCT-116 results in changes of morphology, drug sensitivity and gene expression
42. Altered expression levels in a CPT-resistant cell line: A microarray analysis
43. Different cell thresholds for commitment to death: Link between carcinogenesis and drug resistance
44. Targeting farnesyltransferase: Is RAS relevant?
45. RhoB is required to mediate DNA damage induced apoptosis in transformed cells
46. Mechanisms of resistance to imatinib (ST1571) and prospects for combination with conventional chemotherapeutic agents
47. Mechanisms of resistance to imatinib (ST 1571) in preclinical models and in leukemia patients
48. Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: Progress and therapeutic potential
49. 1 mediate tumor cell resistance to chemotherapy
50. Bcl-2 antisense therapy prolongs survival of gastric cancer in SCID mice
51. Chemosensitisation of malignant melanoma by BCL2 antisense therapy
52. Antisense RNA downregulaation of Bcl-xL protein expression in prostate cancer cells can paradoxically lead to chemo-sensitization
53. Gelatinase-mediated endocytosis: Use for the delivery of apoptosis-inducing reagents into gelatinase-expressing tumor cells
54. Effects of HER-2/neu on chemosensitivity of tumor cells
55. Activation of AKT is required for HER-2/neu-mediated anchorage-independent growth
56. Cytoplasmic localization of p21 (Cip I/WAFI) by Akt-induced phosphorylation in HER-2/neu overexpressing cells
57. PKB/Axt as target for cancer therapy
58. Comparative evaluation of trastuzumab (herceptin) in combination with paclitaxell (taxol) or docetaqxel (taxotere) in Her-2-expressing human breast cancer cell lines
59. Cooperative inhibitory effect of ZD 1839 ('Iressa') in combination with trastuzumab on human breast cancer cell growth
60. Downregulation of the ErbB-2 receptor by trastuzumab (herceptin) enhances TRAIL-mediated apoptosis in breast and ovarian cancer cell lines which overexpress ErbB-2
61. Apoptotic sensitisation in non-small cell lung cancer cells through tyrosine kinase inhibition: Possible role for cytokine signalling and non-receptor tyrosine kinases as regulators of caspase activation and NSCLC cell survival
62. Reactive oxygen metabolism induced by trastuzumab (Herceptin) in human breat cancer cells
63. Hsp90 as an anticancer target
64. Modulation of HSP90 function by ansamycins enhances chemotherapy induced apoptosis in breast cancer cell lines in an RB and schedule-dependent manner
65. Synergistic tumoricidal effect of the paclitaxel and 17-allyl-amino geldanamycin (17AAG) combination in non-small cell lung cancer: In vitro and in vivo analysis
66. 17-Allyl-amino-geldenamycin (17-AAG) induces the degradation of AR and HER-2 in prostate cancer xenograft tumors and inhibitstheir growth
67. The angiogenesis inhibitor bpep-25/Anginex potently inhibits tumor growth in vivo
68. GFB-116, a vascular endothelial growth factor (VEGF) binder, inhibits tumor growth and angiogenesis
69. In vivo and in vitro evaluation if the antitumor and antiangiogenic properties of novel naphthopyrans LY 290181 and LY 290293
70. Growth inhibitory action of 2-methoxyestradiol and its enhancement of the anti-cancer effect of several commonly used chemotherapeutic agents in human breast cancercells regardless of estrogen receptor status
71. Preclinical trial of FB642: Drug effects on differential protein expression in vivo
72. Clinical pharmacodynamics of liposomal lurtotecan (NX 211): Urinary excretion predicts hematologic toxicity
73. Efficacy of NX 211 in SCID mouse models of human leukaemia
74. High performance liquid chromatography-electrospray tandem mass spectrometry procedure for simultaneous quantitation of a camptothecin glycoconjugate, Bay 38-3441, and its lactone metabolite in blood and plasma for pharmacokinetic evaluation diring a phase I study
75. Pre-clinical antitumor activity of 9-nitrc camptothecin
76. Characterization of a class of antifolates that are potent inhibitors of tumor cell growth with in vitro and in vivo activity
77. Metabolism-blocked antifolates, 3: Enantiomers of 4′methylene-5, 8, 10-trideazaa ninopterin
78. Structure-based design of potent inhibitors of CDK I and CDK2
79. Characterization of an inhibitor of human Aurora 2 kinase
80. Indirubins, novel potent inhibitors of cyclin-dependent kinases, inhibit the growth of human xerograft tumors
81. Pharmacokinetic/pharmacodynamic profile of the EGF-receptor inhibitor PK1166 in nude mice bearing NCI H-596 lung tumor xenografts